Clinical Trial Update: Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for Injection [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Recombinant Anti-HER2 humanized monoclonal antibody GB221 in HER-2-positive advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GB221

Snippet

Sponsor: Genor Biopharma Co., Ltd. | Conditions: HER-2-positive Advanced Breast Cancer | Phase 3 | Status: UNKNOWN